• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Cell-free DNA sequencing as a potential screening tool for phase I targeted treatment in refractory/relapse diffuse large B-cell lymphoma.

作者信息

Quivoron Cyril, Tarabay Anthony, Michot Jean-Marie, Pagès Arnaud, Lecourt Hélène, Aupérin Anne, Danu Alina, Lazarovici Julien, Rossignol Julien, Ghez David, Dartigues Peggy, Vergé Véronique, Massard Christophe, Camara-Clayette Valérie, Ribrag Vincent, Sarkozy Clémentine

机构信息

Hematology Translational Research Laboratory, UMS AMMICa, INSERM US23 / CNRS UMS 3655, Gustave Roussy, Villejuif, France; INSERM U1170, Gustave Roussy, Villejuif.

Hematology Department, Gustave Roussy, Villejuif.

出版信息

Haematologica. 2022 Aug 1;107(8):1928-1932. doi: 10.3324/haematol.2021.280464.

DOI:10.3324/haematol.2021.280464
PMID:35320922
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC9335111/
Abstract
摘要
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/536f/9335111/7ed11cd3fe23/1071928.fig1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/536f/9335111/7ed11cd3fe23/1071928.fig1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/536f/9335111/7ed11cd3fe23/1071928.fig1.jpg

相似文献

1
Cell-free DNA sequencing as a potential screening tool for phase I targeted treatment in refractory/relapse diffuse large B-cell lymphoma.游离DNA测序作为难治性/复发性弥漫性大B细胞淋巴瘤I期靶向治疗的潜在筛查工具。
Haematologica. 2022 Aug 1;107(8):1928-1932. doi: 10.3324/haematol.2021.280464.
2
Remarkable response to chidamide plus rituximab in an elderly patient with recurrent, chemotherapy-refractory diffuse larger B-cell lymphoma carrying CREBBP mutation.西达本胺联合利妥昔单抗治疗一名携带CREBBP突变的复发性、化疗难治性弥漫性大B细胞淋巴瘤老年患者疗效显著
Ann Hematol. 2023 May;102(5):1265-1268. doi: 10.1007/s00277-023-05183-9. Epub 2023 Mar 29.
3
Proteomics uncovers molecular features for relapse risk stratification in patients with diffuse large B-cell lymphoma.蛋白质组学揭示弥漫性大B细胞淋巴瘤患者复发风险分层的分子特征。
Blood Cancer J. 2023 Oct 26;13(1):161. doi: 10.1038/s41408-023-00931-6.
4
Molecular attributes underlying central nervous system and systemic relapse in diffuse large B-cell lymphoma.弥漫性大B细胞淋巴瘤中枢神经系统和全身复发的分子特征
Haematologica. 2021 May 1;106(5):1466-1471. doi: 10.3324/haematol.2020.255950.
5
Prognostic impact of CD38 expression in relapsed or refractory diffuse large B-cell lymphoma and follicular lymphoma transformation.CD38表达对复发或难治性弥漫性大B细胞淋巴瘤及滤泡性淋巴瘤转化的预后影响
Leuk Lymphoma. 2022 Jun;63(6):1484-1487. doi: 10.1080/10428194.2021.2024820. Epub 2022 Jan 19.
6
Pathologically complete remission to combination of invariant NK T cells and anti-CD20 antibody in a refractory HIV+ diffuse large B-cell lymphoma patient.NK T 细胞不变性与抗 CD20 抗体联合治疗难治性 HIV 相关弥漫大 B 细胞淋巴瘤患者达到病理完全缓解。
Immunotherapy. 2022 Jun;14(8):599-607. doi: 10.2217/imt-2021-0247. Epub 2022 Apr 20.
7
Evaluation of clinical and biological prognostic factors in relapsed or refractory diffuse large B-cell lymphoma patients after previous treatment with rituximab and chemotherapy: results of the PRO-R-IPI study.利妥昔单抗联合化疗后复发或难治性弥漫性大B细胞淋巴瘤患者临床及生物学预后因素评估：PRO-R-IPI研究结果
Clin Lymphoma Myeloma Leuk. 2015 Jul;15(7):398-403. doi: 10.1016/j.clml.2015.02.029. Epub 2015 Mar 5.
8
Application of next-generation sequencing in diffuse large B-cell lymphoma.下一代测序技术在弥漫性大 B 细胞淋巴瘤中的应用。
Pharmacogenomics. 2023 Jan;24(1):59-68. doi: 10.2217/pgs-2022-0140. Epub 2023 Jan 20.
9
Combination of ibrutinib with rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) for treatment-naive patients with CD20-positive B-cell non-Hodgkin lymphoma: a non-randomised, phase 1b study.伊布替尼联合利妥昔单抗、环磷酰胺、多柔比星、长春新碱和泼尼松（R-CHOP）治疗初治 CD20 阳性 B 细胞非霍奇金淋巴瘤患者：一项非随机、1b 期研究。
Lancet Oncol. 2014 Aug;15(9):1019-26. doi: 10.1016/S1470-2045(14)70311-0. Epub 2014 Jul 17.
10
Rituximab-lenalidomide-dexamethasone induces complete and durable remission in relapsed refractory diffuse large B-cell non-Hodgkin lymphoma.利妥昔单抗-来那度胺-地塞米松可诱导复发难治性弥漫性大B细胞非霍奇金淋巴瘤实现完全且持久的缓解。
Leuk Lymphoma. 2010 Sep;51(9):1758-60. doi: 10.3109/10428194.2010.497886.

本文引用的文献

1
Innovative therapies based on molecular orientation in patients with relapse and refractory diffuse large B-cell lymphoma: Results of LNH-EP1 study.基于分子取向的复发难治性弥漫性大B细胞淋巴瘤患者创新疗法：LNH-EP1研究结果
Am J Hematol. 2021 Oct 1;96(10):E376-E379. doi: 10.1002/ajh.26280. Epub 2021 Jul 10.
2
Genotyping on ctDNA Identifies Shifts in Mutation Spectrum Between Newly Diagnosed and Relapse/Refractory DLBCL.基于循环肿瘤DNA的基因分型可识别初诊与复发/难治性弥漫性大B细胞淋巴瘤之间的突变谱变化。
Onco Targets Ther. 2020 Oct 23;13:10797-10806. doi: 10.2147/OTT.S275334. eCollection 2020.
3
Mutational Landscape and Tumor Burden Assessed by Cell-free DNA in Diffuse Large B-Cell Lymphoma in a Population-Based Study.
基于人群的研究中应用游离 DNA 检测弥漫性大 B 细胞淋巴瘤的突变特征和肿瘤负担
Clin Cancer Res. 2021 Jan 15;27(2):513-521. doi: 10.1158/1078-0432.CCR-20-2558. Epub 2020 Oct 29.
4
Genetic and evolutionary patterns of treatment resistance in relapsed B-cell lymphoma.复发 B 细胞淋巴瘤治疗耐药的遗传和进化模式。
Blood Adv. 2020 Jul 14;4(13):2886-2898. doi: 10.1182/bloodadvances.2020001696.
5
Potential of Circulating Tumor DNA for the Management of Patients With Lymphoma.循环肿瘤 DNA 在淋巴瘤患者管理中的应用潜力。
JCO Oncol Pract. 2020 Sep;16(9):561-568. doi: 10.1200/JOP.19.00691. Epub 2020 May 18.
6
High-Throughput Genomics and Clinical Outcome in Hard-to-Treat Advanced Cancers: Results of the MOSCATO 01 Trial.高通量基因组学与难治疗的晚期癌症的临床结局：MOSCATO 01 试验结果。
Cancer Discov. 2017 Jun;7(6):586-595. doi: 10.1158/2159-8290.CD-16-1396. Epub 2017 Apr 1.
7
The 2016 revision of the World Health Organization classification of lymphoid neoplasms.《世界卫生组织淋巴组织肿瘤分类（2016年修订版）》
Blood. 2016 May 19;127(20):2375-90. doi: 10.1182/blood-2016-01-643569. Epub 2016 Mar 15.
8
Event-free survival at 24 months is a robust end point for disease-related outcome in diffuse large B-cell lymphoma treated with immunochemotherapy.在接受免疫化疗治疗的弥漫性大 B 细胞淋巴瘤患者中，24 个月时无事件生存是疾病相关结局的一个强有力的终点。
J Clin Oncol. 2014 Apr 1;32(10):1066-73. doi: 10.1200/JCO.2013.51.5866. Epub 2014 Feb 18.
9
A general methodology for the analysis of experiments with repeated measurement of categorical data.一种用于分析具有分类数据重复测量的实验的通用方法。
Biometrics. 1977 Mar;33(1):133-58.